Sunovion Pharmaceuticals Inc. (former NASDAQ: SEPR), known until October 12, 2010 as Sepracor, Inc. prior to its acquisition by Sumitomo Pharma of Japan, is a pharmaceutical company founded in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. It was originally located in Princeton, New Jersey and then re-located to Marlborough, Massachusetts. In addition to its headquarters in Marlborough, Sunovion has locations in Mississauga, Ontario, and Teaneck, New Jersey. The company's initial focus was on the separation and purification of isomers and active metabolites. Sepracor completed its initial public offering in 1991 at a market cap of $160M, behind a strategy of presenting larger pharmaceuticals with patented, purified active ingredients for expiring products. In 1993, Marion Merrell Dow, now a part of Sanofi, partnered with Sepracor to develop a purified version of its antihistamine, Seldane, after the latter was required to carry a warning about potentially fatal cardiac arrhythmia. This purified compound would later be marketed as Allegra, but Sepracor would not profit significantly from its launch, a result of less-than favorable partnership terms. More information...
According to PR-model, sunovion.com is ranked 721,830th in multilingual Wikipedia, in particular this website is ranked 442,826th in English Wikipedia.
The website is placed before flipdocs.com and after aalborgzoo.dk in the BestRef global ranking of the most important sources of Wikipedia.
